Study points to potential new approach to treating neurodegenerative diseases like glaucoma and Alzheimer’s disease
Jul. 20, 2020—Researchers at Vanderbilt University Medical Center have shown for the first time that when one optic nerve in the eye is damaged, as in glaucoma, the opposite optic nerve comes to the rescue by sharing its metabolic energy.
Jul. 15, 2019—Vanderbilt Eye Institute researchers have discovered that an imbalance in the ionic environment of retinal ganglion cells may contribute to functional impairments in glaucoma.
Apr. 10, 2018—New findings highlight microRNAs — molecules that regulate gene expression — that are differentially expressed in glaucoma and could be candidate biomarkers or targets for therapy.
Feb. 22, 2018—A team of researchers, led by David Calkins, PhD, vice chair and director of Research at the Vanderbilt Eye Institute, has made a breakthrough discovery in the field of glaucoma showing new hopes for treatments to preserve vision.
Jun. 30, 2017—A signaling molecule called interleukin-6 may be a therapeutic target to prevent vision loss or nerve degeneration in glaucoma, Vanderbilt researchers have discovered.
Dec. 16, 2014—Understanding how the protein TRPV1 helps neurons survive after glaucoma-related stressors could lead to new therapeutic strategies for glaucoma and other neurodegenerative conditions.
Oct. 2, 2014—Vanderbilt University has launched a regenerative visual neuroscience initiative to develop new ways of treating — and restoring sight to — people who have been blinded by glaucoma, macular degeneration, diabetic retinopathy and eye injuries.
Aug. 29, 2014—Vanderbilt University Army ROTC senior Cadet Sean Lee was awarded first place for his research and oral presentation on a new to treatment for glaucoma during the Southeastern Medical Scientist Symposium at Emory University School of Medicine in Atlanta, Saturday.
Mar. 14, 2014—An ion channel protein called TRIPV1 helps retinal neurons survive the elevated eye pressure associated with glaucoma.
Sep. 19, 2013—Three years ago, a team of researchers led by David Calkins, Ph.D., vice chair and director of Research at the Vanderbilt Eye Institute, showed that the first sign of injury in glaucoma, the leading cause of blindness in the United States, occurs in the brain.
Aug. 15, 2013—Suzanne Sousan is not afraid of much.
Jun. 26, 2013—Glaucoma-causing mutations in the gene for myocilin reduce secretion of the protein into the aqueous humor, suggesting a new option for treatment.